Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pilot open-label randomized trial, frozen FMT by nasogastric tube appeared to be as effective as colonoscopic administration in resolving CDIassociated diarrhea. 126”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [126]
In the citing paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [67]
In the citing paper
“FMT has been examined in both young and old, patients with limited comorbidities as well as those considered to be immunocompromised,43 and the procedure has been shown to be safe, well-tolerated, and effective.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“These include complications of endoscopy, such as perforation and bleeding, and side effects related to sedation, such as aspiration43.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839 · cited 1×
“DNA was extracted and the V4 region of the 16S gene was sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].”
MethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569 · cited 1×
“0 [26] approved by the FDA and institutional review board (IRB).”
BackgroundFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 1×
“In the United States the incidence of CDI has tripled over the last 15 years [3].”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Failure to reconstitute normal flora was shown to be a factor in severe, recurrent, and prolonged illness [13].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 1×
“5 guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, at least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.”
BackgroundSelf-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“The work of Hamilton and Khoruts [28] was used as a guide for fecal manipulation, with the exception that all processes were carried out under ambient air, not nitrogen.”
Method
Research works printed but not linked: 1
- 2013, Clostridium difficile infection in children, JAMA Pediatr, 167, 567, 10.1001/jamapediatrics.2013.441 · DOI · Paper page
Cited by
Items 301–400 of 500
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 10
Evaluation of a Screening Method for the Detection of Colistin-Resistant Enterobacteriaceae in Stool
Turbett, S. E., Desrosiers, L., Andrews-Dunleavey, C., Becker, M. V., Walker, A. T., Esposito, D. H., Woodworth, K. R., Branda, J. A., Rosenberg, E. S., Ryan, E. T., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz211 · Cited by 10
Faecal microbiota transplantation: Key points to consider
Bourlioux, P. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.02.001 · Cited by 10
Cao, W., Passot, S., Irlinger, F., & Fonseca, F. (2024) · Foods · doi:10.3390/foods13121809 · Cited by 9
Brittnacher, M., Heltshe, S. L., Hayden, H. S., Radey, M. C., Weiss, E. J., Damman, C. J., Zisman, T. L., Suskind, D. L., & Miller, S. I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158897 · Cited by 9
Faecal transplantation for IBD management—pitfalls and promises
Quraishi, M. N., Critchlow, T., Bhala, N. B., Sharma, N., & Iqbal, T. H. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx040 · Cited by 9
New and emerging therapies in treatment of Clostridium difficile infection
Goyal, H., Perisetti, A., Rehman, M., & Singla, U. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001103 · Cited by 9
In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
Binyamin, D., Nitzan, O., Azrad, M., Hamo, Z., Koren, O., & Peretz, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01256 · Cited by 9
“In severe and recurrent cases, fecal microbiota transplantation, a treatment that restores the normal fecal microbiota, is efficacious (Youngster et al., 2014).”
BackgroundKaako, A., Al-Amer, M., & Abdeen, Y. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.11.010 · Cited by 9
Liu, M., Hu, Y., Xu, M.-D., Chen, Y., & Meng, Q.-B. (2026) · Food & medicine homology. · doi:10.26599/fmh.2027.9420146 · Cited by 8
Recent advances in managing lower urinary tract infections
Lee, S. (2018) · F1000Research · doi:10.12688/f1000research.16245.1 · Cited by 8
Rupawala, A., Gachette, D., Bakhit, M., Jimoh, L., & Kelly, C. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab041 · Cited by 8
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · BMC Veterinary Research · doi:10.1186/s12917-024-04166-w · Cited by 8
“Several controlled trials have demonstrated no difference in efficacy between fresh and frozen transplant material for treatment of CDI [4, 7, 9].”
BackgroundCruz, R., Monrroy, H., Flandez, J., Pérez, C. M., Álvarez-Lobos, M., & Hernández-Rocha, C. (2018) · Revista chilena de infectología · doi:10.4067/s0716-10182018000500566 · Cited by 8
(2019) · Global Clinical and Translational Research · doi:10.20900/gctr20190004 · Cited by 8
Fecal Microbiota Transplantation Research over the Past Decade: Current Status and Trends
Hao, S., Yang, S., Zhang, N., & Cheng, H.-J. (2023) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2023/6981721 · Cited by 8
Feces transplantation for recurrentClostridium difficileinfection: US experience and recommendations
Bakken, J. (2015) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v26.27657 · Cited by 8
“Youngster recently reported that human feces may also be successfully administered using pre-screened frozen fecal gel capsules, noting a success-rate of 70% (19).”
BackgroundLin, Z., Iqbal, Z., Ortíz, J. F., Khan, S. A., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9653 · Cited by 8
Encapsulation protocol for fecal microbiota transplantation
Sipos, D., Varga, A., Kappéter, Á., Halda-Kiss, B., Kása, P., Pál, S., Kocsis, B., & Péterfi, Z. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1424376 · Cited by 8
Batista, R., Kapel, N., Megerlin, F., Chaumeil, J. C., Barbut, F., Bourlioux, P., & Chast, F. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.02.004 · Cited by 8
Stuhltransplantation beim Rezidiv der Clostridium-difficile-Kolitis
Ramsauer, B., König, C., Sabelhaus, T., Ockenga, J., & Otte, J. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-8305-y · Cited by 8
Faecal microbiota transplantation
(2014) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2014.12.0298 · Cited by 8
Fecal Microbiota Transplantation: Do We Need Harmonization?
Galpérine, T., Sokol, H., & Guery, B. P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix092 · Cited by 8
Wu, L.-Q., Yuan, Q., Wu, L., Xia, H. H., Zhong, M., Liu, T., Ye, X., Luo, D.-P., Xu, J., Xie, W.-R., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02929-7 · Cited by 7
“There have been some studies to evaluate the various routes of WMT administration in Clostridioides difficile infection [44, 45] However, there is no reported difference in the efficacy among the different delivery routes for the treatment of FC.”
BackgroundVinterberg, J. E., Oddsdottir, J., Nye, M., & Pinton, P. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01105-y · Cited by 7
“Among the reviewed trials, information regarding the time since initial CDI diagnosis and the duration of the qualifying CDI episode [27, 30, 31, 35] and five trials [13, 26, 27, 29, 33, 34] respectively, with noticeable variations in the reported data.”
InfluentialDuo, H., Yang, Y., Zhang, G., Chen, Y., Cao, Y., Luo, L., Pan, H., & Ye, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1430724 · Cited by 7
Roggenbrod, S., Schuler, C., Haller, B., Sohn, M., Storr, M., Schepp, W., & Gundling, F. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0821-7166 · Cited by 7
“[22] Youngster I, Sauk J, Pindar C et al.”
BackgroundOpportunities for Nanomedicine in Clostridioides difficile Infection
Wang, P., Lee, W., Wu, Y., & Shieh, D. (2021) · Antibiotics · doi:10.3390/antibiotics10080948 · Cited by 7
“Further clinical studies showed that FMT successfully cured patients with recurrent CDI and attenuated CDI-associated diarrhea [76,77].”
BackgroundFecal Microbiota Transplantation
Borody, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00018-0 · Cited by 7
Felipe Moscoso, J., Simian, D., Rivera, D., Guillermo Acuña, L., & Quera, R. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015000400017 · Cited by 7
Recent Issues in Pediatric Clostridium difficile Infection
Clayton, J. A., & Toltzis, P. (2017) · Current Infectious Disease Reports · doi:10.1007/s11908-017-0603-8 · Cited by 7
Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?
Farha, J., Abbarh, S., Haq, Z., Itani, M. I., Oberbach, A., Kumbhari, V., & Badurdeen, D. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-00798-8 · Cited by 7
Kenna, T., Hanson, A., Costello, M., & Brown, M. A. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0612-x · Cited by 7
Walton, J., Burns, D., & Gaehle, K. E. (2017) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000233 · Cited by 7
Tempered Enthusiasm for Fecal Transplantation?
Högenauer, C., Kump, P. K., & Krause, R. G. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu567 · Cited by 7
Meeting update: faecal microbiota transplantation––bench, bedside, courtroom?
Ding, N. S., Mullish, B. H., McLaughlin, J. T., Hart, A. L., & Marchesi, J. R. (2016) · Frontline Gastroenterology · doi:10.1136/flgastro-2016-100752 · Cited by 6
Sintes, R., McLellan, P., Navelli, G., Landman, C., Delage, S., Truong, S., Benech, N., Kapel, N., Sabater, A. M., Schnuriger, A., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00734-24 · Cited by 6
Gîlcă-Blanariu, G.-E., Ștefănescu, G., Gîrleanu, I., Iqbal, T. H., Segal, J. P., Mullish, B. H., Quraishi, M. N., Keller, J. J., Molnár, T., Mégraud, F., et al. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3297 · Cited by 6
“However, FMT has also been successfully performed with donor feces from unrelated healthy volunteers [96].”
BackgroundZyoud, S. H., Shakhshir, M. H., Abushanab, A. S., Koni, A. A., Shahwan, M. J., Jairoun, A. A., Taha, A. A., & Al‐Jabi, S. W. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i26.6132 · Cited by 6
Microbiota: In Health and in Sickness, From Birth to Death
Kuk, S., Uyar, Y., Karaca, S., & Yazar, S. (2016) · Turkish Journal of Parasitology · doi:10.5152/tpd.2016.4789 · Cited by 6
Trinh, S., Keller, L., Herpertz‐Dahlmann, B., & Seitz, J. (2023) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000928 · Cited by 5
Validation methods for encapsulated faecal microbiota transplantation: a scoping review
Rågård, N., Baunwall, S. M. D., Paaske, S. E., Hansen, M. M., Høyer, K. L., Mikkelsen, S., Erikstrup, C., Dahlerup, J. F., & Hvas, C. L. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251314820 · Cited by 5
Shaheen, M. N., McDougall, C., Chan, L., Franz, R., Wong, K., Giebelhaus, R. T., Nguyen, G., Nam, S. L., de la Mata, A. P., Yeo, S., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13030587 · Cited by 5
“The fecal microbiota transplant (FMT) is currently the most effective treatment for CDI, irrespective of the route of administration [3], with clinical efficacies of >80% in randomized controlled trials (RCT) [4–7], and has been recommended by multiple practice guidelines for managing rCDI [8,9].”
Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice
Rossier, L., Matter, C., Burri, E., Galpérine, T., Hruz, P. L., Juillerat, P., Schoepfer, A. M., Vavricka, S. R., Zahnd, N., Décosterd, N., et al. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40100 · Cited by 6
“Its efficiency in Clostridioides difficile infection has been demonstrated, and it could be more appealing because it is less invasive than colonoscopy, especially in patients with an inflamed bowel [2, 110, 111].”
BackgroundClostridium difficile infection: current, forgotten and emerging treatment options
Drekonja, D. M. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.36 · Cited by 5
Multiscale analysis of the murine intestine for modeling human diseases
Lyons, J., Herring, C. A., Banerjee, A., Simmons, A. J., & Lau, K. S. (2015) · Integrative Biology · doi:10.1039/c5ib00030k · Cited by 5
Zhang, C., Virk, A. K., KHAN, I. A., & Qin, H. (2020) · Springer eBooks · doi:10.1007/978-981-15-4759-1_2 · Cited by 5
Pediatric Fecal Microbiota Transplantation in Recurrent Clostridioides Difficile
Parnell, J. M., Nicholson, M. R., Kellermayer, R., & Kahn, S. A. (2021) · Pediatric Annals · doi:10.3928/19382359-20211111-01 · Cited by 5
Kashyap, S., & Das, A. (2023) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2023.02054 · Cited by 5
Roy, T. L., Aron‐Wisnewsky, J., & Clément, K. (2020) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2019.12.001 · Cited by 5
THE POWER OF POOP: FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIUM DIFFICILE INFECTION.
Edmond, M. B. (2016) · PubMed Central · Cited by 5
Fecal Microbiota Transplantation forClostridium difficileInfection
Armstrong, M. J., Pathmakanthan, S., & Iqbal, T. H. (2015) · JAMA · doi:10.1001/jama.2014.18617 · Cited by 5
Editorial: a simple faecal preparation protocol for faecal microbiota transplantation
Kelly, C. R. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13039 · Cited by 5
Should the Faecal Microbiota Composition Be Determined to Certify a Faecal Donor?
Morales, C., Ballestero, L., del Río, P., Barbero-Herranz, R., Olavarrieta, L., Gomez-Artiguez, L., Galeano, J., Ortiz, J. A., Basterra, J., & del Campo, R. (2024) · Diagnostics · doi:10.3390/diagnostics14232635 · Cited by 4
“The results shown above coupled with the observation that frozen and fresh faeces have the same effect and safety [35,36] gave rise to numerous stool banks and biopharma-ceutical companies focused on the development of drugs based on the human microbiome.”
Fecal Microbiota Transplantation as Emerging Treatment in European Countries 2.0
Porcari, S., Maida, M. F., Bibbò, S., Mcilroy, J. R., Ianiro, G., & Cammarota, G. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-42108-2_5 · Cited by 4
Effects of Different Feed Additives on Intestinal Metabolite Composition of Weaned Piglets
Zhao, M., Zhang, J., Liu, F., Luo, L., Wei, M., Ye, Y., Chamba, Y., & Shang, P. (2024) · Metabolites · doi:10.3390/metabo14030138 · Cited by 4
Sedeek, S. A., Farowski, F., Youssafi, S., Tsakmaklis, A., Brodesser, S., El-Attar, M., Abdelmalek, M. O., & Vehreschild, M. J. G. T. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04291-0 · Cited by 4
“FMT products stored at -80 °C are now routinely used, and multiple randomized controlled trials have proven that it is as effective as fresh suspensions in terms of rCDI cure rates (Youngster et al. 2014 ; Lee et al. 2016 ; Gangwani et al. 2023).”
Das Mikrobiom des Darms beim kritisch kranken Patienten
Salzberger, B., & Rauscher, C. (2015) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-015-0078-z · Cited by 4
Joshi, S., & Navinskey, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805376-8.00006-x · Cited by 4
Gut microbes as a therapeutic armory
Bhardwaj, N., & Geva‐Zatorsky, N. (2018) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2019.08.007 · Cited by 4
Self-stool banking as a source for fecal microbiota transplantation: A pilot study
Raybardhan, S., Ng, W., Tomassi, J., & Katz, K. C. (2017) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi.2.1.002 · Cited by 4
Quera, R., Sedaño, R., Espinoza, R., & Rivera, D. (2019) · Revista chilena de infectología · doi:10.4067/s0716-10182019000400536 · Cited by 4
The levels and core delivery ways of gut microbial reconstruction
Lu, G., & Zhang, F. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0381 · Cited by 4
Bakker, G. J., & Nieuwdorp, M. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch12 · Cited by 4
On the Stability Landscape of the Human Gut Microbiome: Implications for Microbiome-based TherapiesPreprint
Gibson, T. E., Carey, V. J., Bashan, A., Hohmann, E. L., Weiss, S. T., & Liu, Y. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/176941 · Cited by 4
Self-citationVestal, R. (2015) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2015.08.006 · Cited by 3
Clostridium difficile Infections in Hospitals and Community
Bauer, M. P., & Kuijper, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00040-x · Cited by 3
Faecal microbiota transplantation: what’s beyond Clostridium difficile infection?
Tamilarasan, A. G., & Krishnananthan, T. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001938 · Cited by 3
Clostridium difficile Infection
Shin, J. H., Chaves‐Olarte, E., & Warren, C. A. (2016) · ASM Press eBooks · doi:10.1128/9781555819453.ch15 · Cited by 3
FMT in Clostridium difficile and Other Potential Uses
Fine, S., & Kelly, C. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00034-3 · Cited by 3
Clostridium difficile : What the surgeon needs to know
Hrebinko, K. A., & Zuckerbraun, B. S. (2017) · Seminars in Colon and Rectal Surgery · doi:10.1053/j.scrs.2017.09.006 · Cited by 3
Current Status of Fecal Microbiota Transplantation
Reygner, J., & Kapel, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00016-6 · Cited by 3
Fekal Mikrobiyota Transplantasyonu Ve Hemşirelik
Bıkmaz, Z., & Çiçek, M. (2020) · Journal of General Health Sciences (JGEHES) Necmettin Erbakan University · Cited by 3
Fecal Microbiota Transplantation forClostridium difficileInfection—Reply
Youngster, I., & Hohmann, E. L. (2015) · JAMA · doi:10.1001/jama.2014.18619 · Cited by 3
Self-citationSolari, P. R., & Wallace, M. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu568 · Cited by 3
Fecal microbiota transplantation - something more than merely a therapeutic curiosity
Ferre‐Aracil, C., Aguilera, L., de Santiago, E. R., de Paredes, A. G. G., & López–Sanromán, A. (2015) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2015.3875/2015 · Cited by 3
Chen, L., Chen, C., Bai, Y., Li, C., Wei, C., Wei, R., Luo, R., Li, R., Ma, Q., & Geng, Y. (2025) · International Microbiology · doi:10.1007/s10123-025-00663-6 · Cited by 2
“Frozen fecal material is now widely used, and several randomized controlled trials have confirmed that the use of frozen-and-thawed material is not inferior (in terms of cure rates for rCDI) to the application of fresh material (Lee et al. 2016; Nood et al. 2013; Youngster et al. 2014).”
Ni, Z., Xie, J., Zhang, Z., Zhang, K., Ding, J., Chang, M., Su, Y., Zhang, Y., Yao, M., Wang, C., et al. (2026) · iMeta · doi:10.1002/imt2.70148 · Cited by 2
Stool donor recruitment – A one-year experience
Aira, A., Rubio-García, E., Fehér, C., González-Suárez, B., Casals‐Pascual, C., & Soriano, À. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.01.018 · Cited by 2
Minimum Requirements for Reporting Fecal Microbiota Transplant Trial.
Moossavi, S., Bishehsari, F., Ansari, R., Vahedi, H., Nasseri‐Moghaddam, S., Merat, S., Sobhani, I., Keshavarzian, A., & Malekzadeh, R. (2015) · PubMed Central · Cited by 2
Clostridium difficile Infection: Current and Emerging Therapeutics
Jarrad, A. M., Blaskovich, M. A. T., Lyras, D., & Cooper, M. A. (2015) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-015-0062-4 · Cited by 2
Ampel, N. M. (2014) · Journal watch · doi:10.1056/nejm-jw.na34609 · Cited by 2
Fecal Microbiota Transplants: Current Knowledge and Future Directions
Chis, R., Sheth, P. M., & Petrof, E. O. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7534-1_11 · Cited by 2
Faecal microbiota transplantation for refractory C lostridium difficile infection
Tamilarasan, A. G., Irving, P. M., Meadows, C. I. S., & Goldenberg, S. D. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-231027 · Cited by 2
Kozlov, R. S., Shelygin, Y. A., Veselov, A. V., Dekhnich, A. V., Zubareva, N., Ershova, O. N., Кулабухов, В. В., Попов, Д. А., Reshedko, G., & Yakushin, S. B. (2018) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2018.2.76-124 · Cited by 2
Marsh, J. W., & Harrison, L. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801214-7.00010-7 · Cited by 2
Stool donor recruitment – A one-year experience
Aira, A., Rubio-García, E., Fehér, C., González-Suárez, B., Casals‐Pascual, C., & Soriano, À. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2021.01.010 · Cited by 2
Stuntz, M., & Vignes, F. D. (2015) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2015.11.001 · Cited by 2
Faecal transplantation and infectious diseases practitioners
Raoult, D. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12790 · Cited by 2
“Different routes can be used, such as fibroscopy through duodenal injection, colonic inoculation, or nasogastric tubes [9].”
BackgroundThe antimicrobial and bile acid mediated control of Clostridium difficile infection
Dempster, A. W. (2018) · Nottingham ePrints (University of Nottingham) · Cited by 2
Wilson, G., Petersen, C. A., Schweizer, M. L., Breheny, P. J., Charlton, M. E., Perencevich, E. N., & Nonnenmann, M. (2019) · doi:10.17077/etd.cp4w-j0zs · Cited by 2
Nicolas, S. (2016) · theses.fr (ABES) · doi:10.70675/9bfdcec7z8f9az4d52z9c72z5f2dd4c6ad5e · Cited by 2
Donor Screening for Fecal Microbiota Transplantation
Lee, H. H., & Cho, Y. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.3.181 · Cited by 1
“이러한 제외 기준을 만족한 기증자에게서 시 행된 FMT의 경우, 부작용이 거의 나타나지 않음이 여러 연 구에서 확인되었다[4,5,10,19,20,28,29].”
Silva, M. A. M., Barud, M. D. L., Barkett, G. V., Almeida, M. E. G., & Leão, M. V. P. (2022) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2022/v34i2231588 · Cited by 1
“[15] studying different administration routes of FMT in RCDI patients, demonstrated, through a randomized-controlled trial, that the administration of fecal microbiota by nasogastric tube was as effective as administration via colonoscopy.”
BackgroundMohandas, S., Farid, S., & Michail, S. K. (2020) · Journal of Medicine and Therapeutics · doi:10.15761/jmt.1000147 · Cited by 1
“Indeed, FMT has successfully been used in the management of recurrent CDI (rCDI) in adults with several high quality RCTs demonstrating efficacy, with cure rates approaching 90% [60-65].”
Bzdyra, M., Tulewicz-Marti, E. M., Przepióra, A., Lewandowski, K., & Rydzewska, G. M. (2025) · Gastroenterology Review · doi:10.5114/pg.2025.154701 · Cited by 3
“According to randomised trials, donor FMTs were more efficient then autologous [15], with a high symptom resolution of 75–94% [16, 17].”
Junior, D. M. D. S., Martins, G. C., Ferreira-Moura, T. A., Ordine, J. V. W., & Zaramela, L. S. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2603859 · Cited by 1
Strain-level ecological filtering governs microbial colonization of the human gut
Baertschi, I., Jordi, S. B. U., Gardaz, L. J., Bigi, F. V., Sokollik, C., Juillerat, P., & Yılmaz, B. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117775 · Cited by 1
Fecal Microbial Transplant: For Whom, How, and When
Kahn, S. A., & Kaplan, J. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-17169-2_35 · Cited by 1
Self-citationRussell, G. H. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000619 · Cited by 1
Self-citation
Metadata
- Authors
- Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Youngster, Ilan
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 58
- Issue
- 11
- Pages
- 1515-1522
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4017893
- OpenAlex
- W2146116383
- Cited by
- 467
- References
- 32
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 31 · 2023: 22 · 2022: 24 · 2021: 35 · 2020: 37 · 2019: 51 · 2018: 47 · 2017: 57 · 2016: 53 · 2015: 61 · 2014: 27
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000170)
- National Institute of Allergy and Infectious Diseases (HHSN272200900018C)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, unrelated donor, nasogastric tube administration, diarrhea resolution, health-related quality of life, antibiotic-refractory infection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy, Child, Clostridium Infections, Colonoscopy, Diarrhea, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.